Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues
Background/Aims: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients. Methods: We searched the Web of...
Gespeichert in:
| Veröffentlicht in: | Cellular Physiology and Biochemistry 2018-05, Vol.46 (4), p.1643-1649 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1649 |
|---|---|
| container_issue | 4 |
| container_start_page | 1643 |
| container_title | Cellular Physiology and Biochemistry |
| container_volume | 46 |
| creator | Zhu, Zheng-ming Liu, Fang-teng Chen, Xuan |
| description | Background/Aims: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients. Methods: We searched the Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and the Wanfang database to identify studies evaluating the prognostic value of lncRNA CASC2 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models. Results: A total of eight studies were included. The combined results showed that lncRNA CASC2 was significantly associated with decreased overall survival (OS) (HR = 0.37, 95% CI, 0.27–0.46, P < 0.001). Subgroup analyses further indicated that low expression of lncRNA CASC2 predicted decreased OS in cancer patients. Additionally, low CASC2 expression levels in cancer tissues appeared to be correlated with advanced clinical staging (OR = 3.32, 95% CI, 2.29–4.80, P < 0.001). Conclusions: Low CASC2 expression appears to be predictive of poor OS and advanced tumor stage in multiple cancers. CASC2 expression may serve as unfavorable prognostic factor for clinical outcomes in cancer patients. |
| doi_str_mv | 10.1159/000489211 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000489211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A637524459</galeid><doaj_id>oai_doaj_org_article_8931f79069f540478249b21321776c5b</doaj_id><sourcerecordid>A637524459</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-17e301c31298545741ddfad73b11cb81bd65ff5934d48b201a438257e58931d93</originalsourceid><addsrcrecordid>eNptkUtv1DAUhSMEog9YsEfIUjdlMcXXj9heDqMClUaAaFlbjh8jD5l4sBNB_z0e0s4CoSx8ffOdax-fpnkF-AqAq3cYYyYVAXjSnAIjsFBCyKe1xsAXUklx0pyVssV1KxR53pwQ1SqmWn7abNfpF7r-vc--lJgGlAJaD_bb5yVamcH6jG6nYv1-jF3s43h_6LrozOgRQbVEcSxo1cchWtOj27gZYqhlVaI4PI64i6VMvrxongXTF__yYT1vvn-4vlt9Wqy_fLxZLdcLyykeFyA8xWApECU544KBc8E4QTsA20noXMtD4Ioyx2RHMBhGJeHCc6koOEXPm5t5rktmq_c57ky-18lE_beR8kabPEbbe31QBKFwqwJnmAlJmOoIUAJCtJZ3ddblPGuf08_qYdS7WN-j783g01Q0wRQYAAFZ0Yt_0G2a8lCd6pqMgLZtCavU1UxtTD0_DiGN2dj6Ob-LNg0-xNpftlRwwhg_uHk7C2xOpWQfjo4A60P6-ph-Zd88XGHqdt4dyce4K_B6Bn6YvPH5CBz1F__9vfr6fib03gX6B0Yrudw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2117166624</pqid></control><display><type>article</type><title>Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Karger Open Access Journals</source><creator>Zhu, Zheng-ming ; Liu, Fang-teng ; Chen, Xuan</creator><creatorcontrib>Zhu, Zheng-ming ; Liu, Fang-teng ; Chen, Xuan</creatorcontrib><description>Background/Aims: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients. Methods: We searched the Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and the Wanfang database to identify studies evaluating the prognostic value of lncRNA CASC2 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models. Results: A total of eight studies were included. The combined results showed that lncRNA CASC2 was significantly associated with decreased overall survival (OS) (HR = 0.37, 95% CI, 0.27–0.46, P < 0.001). Subgroup analyses further indicated that low expression of lncRNA CASC2 predicted decreased OS in cancer patients. Additionally, low CASC2 expression levels in cancer tissues appeared to be correlated with advanced clinical staging (OR = 3.32, 95% CI, 2.29–4.80, P < 0.001). Conclusions: Low CASC2 expression appears to be predictive of poor OS and advanced tumor stage in multiple cancers. CASC2 expression may serve as unfavorable prognostic factor for clinical outcomes in cancer patients.</description><identifier>ISSN: 1015-8987</identifier><identifier>EISSN: 1421-9778</identifier><identifier>DOI: 10.1159/000489211</identifier><identifier>PMID: 29694965</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Biomarkers ; Cancer patients ; Cancer susceptibility candidate 2 ; Care and treatment ; Cell growth ; Cell Line, Tumor ; Cervical cancer ; Clinical significance ; Databases, Factual ; Disease susceptibility ; Down-Regulation ; Esophagus ; Gastric cancer ; Genetic aspects ; Health aspects ; Humans ; Liver cancer ; Long noncoding RNA ; Lung cancer ; Medical prognosis ; Meta-analysis ; Multivariate analysis ; Neoplasm Staging ; Neoplasms - metabolism ; Neoplasms - mortality ; Neoplasms - pathology ; Odds Ratio ; Original Paper ; Overall survival ; Pancreatic cancer ; Prognosis ; Proportional Hazards Models ; Risk factors ; RNA ; RNA, Long Noncoding - genetics ; RNA, Long Noncoding - metabolism ; Survival Rate ; Thyroid cancer ; Tumor stage ; Tumor Suppressor Proteins - genetics ; Tumorigenesis</subject><ispartof>Cellular Physiology and Biochemistry, 2018-05, Vol.46 (4), p.1643-1649</ispartof><rights>2018 The Author(s). Published by S. Karger AG, Basel</rights><rights>2018 The Author(s). Published by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2018 S. Karger AG</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-17e301c31298545741ddfad73b11cb81bd65ff5934d48b201a438257e58931d93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,2096,27612,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29694965$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Zheng-ming</creatorcontrib><creatorcontrib>Liu, Fang-teng</creatorcontrib><creatorcontrib>Chen, Xuan</creatorcontrib><title>Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues</title><title>Cellular Physiology and Biochemistry</title><addtitle>Cell Physiol Biochem</addtitle><description>Background/Aims: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients. Methods: We searched the Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and the Wanfang database to identify studies evaluating the prognostic value of lncRNA CASC2 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models. Results: A total of eight studies were included. The combined results showed that lncRNA CASC2 was significantly associated with decreased overall survival (OS) (HR = 0.37, 95% CI, 0.27–0.46, P < 0.001). Subgroup analyses further indicated that low expression of lncRNA CASC2 predicted decreased OS in cancer patients. Additionally, low CASC2 expression levels in cancer tissues appeared to be correlated with advanced clinical staging (OR = 3.32, 95% CI, 2.29–4.80, P < 0.001). Conclusions: Low CASC2 expression appears to be predictive of poor OS and advanced tumor stage in multiple cancers. CASC2 expression may serve as unfavorable prognostic factor for clinical outcomes in cancer patients.</description><subject>Biomarkers</subject><subject>Cancer patients</subject><subject>Cancer susceptibility candidate 2</subject><subject>Care and treatment</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cervical cancer</subject><subject>Clinical significance</subject><subject>Databases, Factual</subject><subject>Disease susceptibility</subject><subject>Down-Regulation</subject><subject>Esophagus</subject><subject>Gastric cancer</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Long noncoding RNA</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - pathology</subject><subject>Odds Ratio</subject><subject>Original Paper</subject><subject>Overall survival</subject><subject>Pancreatic cancer</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Risk factors</subject><subject>RNA</subject><subject>RNA, Long Noncoding - genetics</subject><subject>RNA, Long Noncoding - metabolism</subject><subject>Survival Rate</subject><subject>Thyroid cancer</subject><subject>Tumor stage</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumorigenesis</subject><issn>1015-8987</issn><issn>1421-9778</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkUtv1DAUhSMEog9YsEfIUjdlMcXXj9heDqMClUaAaFlbjh8jD5l4sBNB_z0e0s4CoSx8ffOdax-fpnkF-AqAq3cYYyYVAXjSnAIjsFBCyKe1xsAXUklx0pyVssV1KxR53pwQ1SqmWn7abNfpF7r-vc--lJgGlAJaD_bb5yVamcH6jG6nYv1-jF3s43h_6LrozOgRQbVEcSxo1cchWtOj27gZYqhlVaI4PI64i6VMvrxongXTF__yYT1vvn-4vlt9Wqy_fLxZLdcLyykeFyA8xWApECU544KBc8E4QTsA20noXMtD4Ioyx2RHMBhGJeHCc6koOEXPm5t5rktmq_c57ky-18lE_beR8kabPEbbe31QBKFwqwJnmAlJmOoIUAJCtJZ3ddblPGuf08_qYdS7WN-j783g01Q0wRQYAAFZ0Yt_0G2a8lCd6pqMgLZtCavU1UxtTD0_DiGN2dj6Ob-LNg0-xNpftlRwwhg_uHk7C2xOpWQfjo4A60P6-ph-Zd88XGHqdt4dyce4K_B6Bn6YvPH5CBz1F__9vfr6fib03gX6B0Yrudw</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Zhu, Zheng-ming</creator><creator>Liu, Fang-teng</creator><creator>Chen, Xuan</creator><general>S. Karger AG</general><general>Cell Physiol Biochem Press GmbH & Co KG</general><scope>M--</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20180501</creationdate><title>Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues</title><author>Zhu, Zheng-ming ; Liu, Fang-teng ; Chen, Xuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-17e301c31298545741ddfad73b11cb81bd65ff5934d48b201a438257e58931d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomarkers</topic><topic>Cancer patients</topic><topic>Cancer susceptibility candidate 2</topic><topic>Care and treatment</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cervical cancer</topic><topic>Clinical significance</topic><topic>Databases, Factual</topic><topic>Disease susceptibility</topic><topic>Down-Regulation</topic><topic>Esophagus</topic><topic>Gastric cancer</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Long noncoding RNA</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - pathology</topic><topic>Odds Ratio</topic><topic>Original Paper</topic><topic>Overall survival</topic><topic>Pancreatic cancer</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Risk factors</topic><topic>RNA</topic><topic>RNA, Long Noncoding - genetics</topic><topic>RNA, Long Noncoding - metabolism</topic><topic>Survival Rate</topic><topic>Thyroid cancer</topic><topic>Tumor stage</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Zheng-ming</creatorcontrib><creatorcontrib>Liu, Fang-teng</creatorcontrib><creatorcontrib>Chen, Xuan</creatorcontrib><collection>Karger Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cellular Physiology and Biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Zheng-ming</au><au>Liu, Fang-teng</au><au>Chen, Xuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues</atitle><jtitle>Cellular Physiology and Biochemistry</jtitle><addtitle>Cell Physiol Biochem</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>46</volume><issue>4</issue><spage>1643</spage><epage>1649</epage><pages>1643-1649</pages><issn>1015-8987</issn><eissn>1421-9778</eissn><abstract>Background/Aims: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients. Methods: We searched the Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and the Wanfang database to identify studies evaluating the prognostic value of lncRNA CASC2 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models. Results: A total of eight studies were included. The combined results showed that lncRNA CASC2 was significantly associated with decreased overall survival (OS) (HR = 0.37, 95% CI, 0.27–0.46, P < 0.001). Subgroup analyses further indicated that low expression of lncRNA CASC2 predicted decreased OS in cancer patients. Additionally, low CASC2 expression levels in cancer tissues appeared to be correlated with advanced clinical staging (OR = 3.32, 95% CI, 2.29–4.80, P < 0.001). Conclusions: Low CASC2 expression appears to be predictive of poor OS and advanced tumor stage in multiple cancers. CASC2 expression may serve as unfavorable prognostic factor for clinical outcomes in cancer patients.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>29694965</pmid><doi>10.1159/000489211</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1015-8987 |
| ispartof | Cellular Physiology and Biochemistry, 2018-05, Vol.46 (4), p.1643-1649 |
| issn | 1015-8987 1421-9778 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000489211 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Karger Open Access Journals |
| subjects | Biomarkers Cancer patients Cancer susceptibility candidate 2 Care and treatment Cell growth Cell Line, Tumor Cervical cancer Clinical significance Databases, Factual Disease susceptibility Down-Regulation Esophagus Gastric cancer Genetic aspects Health aspects Humans Liver cancer Long noncoding RNA Lung cancer Medical prognosis Meta-analysis Multivariate analysis Neoplasm Staging Neoplasms - metabolism Neoplasms - mortality Neoplasms - pathology Odds Ratio Original Paper Overall survival Pancreatic cancer Prognosis Proportional Hazards Models Risk factors RNA RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism Survival Rate Thyroid cancer Tumor stage Tumor Suppressor Proteins - genetics Tumorigenesis |
| title | Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A03%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20Expression%20of%20LncRNA%20Cancer%20Susceptibility%20Candidate%202%20and%20its%20Clinical%20Significance%20in%20Cancer%20Tissues&rft.jtitle=Cellular%20Physiology%20and%20Biochemistry&rft.au=Zhu,%20Zheng-ming&rft.date=2018-05-01&rft.volume=46&rft.issue=4&rft.spage=1643&rft.epage=1649&rft.pages=1643-1649&rft.issn=1015-8987&rft.eissn=1421-9778&rft_id=info:doi/10.1159/000489211&rft_dat=%3Cgale_cross%3EA637524459%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2117166624&rft_id=info:pmid/29694965&rft_galeid=A637524459&rft_doaj_id=oai_doaj_org_article_8931f79069f540478249b21321776c5b&rfr_iscdi=true |